Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Ophthalmology | Monthly Briefing

Back to Journal Articles

August 2012 Briefing - Ophthalmology

Last Updated: September 04, 2012.

 

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 

Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for August 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Low HDL Cholesterol Ups Risk of Diabetic Nephropathy

WEDNESDAY, Aug. 22 (HealthDay News) -- High-density lipoprotein cholesterol (HDL-C) is an independent risk factor for the development of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes, according to research published online Aug. 13 in Diabetes Care.

Abstract
Full Text (subscription or payment may be required)

Vitreolytic Ocriplasmin Resolves Vitreomacular Traction

THURSDAY, Aug. 16 (HealthDay News) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according to a study published in the Aug. 16 in the New England Journal of Medicine.

Full Text (subscription or payment may be required)

Contact Lens Sensor Measures 24-Hour Intraocular Pressure

WEDNESDAY, Aug. 15 (HealthDay News) -- A contact lens sensor (CLS) provides safe and tolerable 24-hour monitoring of intraocular pressure (IOP) patterns in patients with or suspected of having glaucoma, according to research published online Aug. 13 in the Archives of Ophthalmology.

Abstract
Full Text (subscription or payment may be required)

Poor Follow-Up of Hospital Tests Often Due to Late Orders

TUESDAY, Aug. 14 (HealthDay News) -- Poor follow-up of test results at or after discharge from the hospital is often due to tests requested on the day of discharge, according to a letter to the editor published online Aug. 13 in the Archives of Internal Medicine.

Full Text (subscription or payment may be required)

Novel System Improves Retinal Prostheses in Mouse Model

TUESDAY, Aug. 14 (HealthDay News) -- A visual prosthetic that mimics normal retinal processing is able to improve retinal prosthetic capability in a mouse model of retinal degeneration, according to a study published online Aug. 13 in the Proceedings of the National Academy of Sciences.

Abstract
Full Text (subscription or payment may be required)

Cataract Risk Up for Statin Users With Type 2 Diabetes

MONDAY, Aug. 13 (HealthDay News) -- Statin use, which is substantially higher in patients with type 2 diabetes, correlates with an increased risk of age-related (AR) cataracts, according to a study published in the August issue of Optometry and Vision Science.

Abstract
Full Text

Lucentis Approved for Diabetic Macular Edema

FRIDAY, Aug. 10 (HealthDay News) -- Lucentis (ranibizumab injection) has been approved by the U.S. Food and Drug Administration to treat diabetic macular edema (DME), an eye condition that can threaten the sight of those with diabetes, the agency said Friday in a news release.

diabetic eye disease

Lack of Sleep Affects Speed, Not Accuracy of Visual Tasks

FRIDAY, Aug. 3 (HealthDay News) -- Sleep deprivation and circadian rhythm disruptions impact the speed, but not the accuracy, with which complex visual tasks are performed, according to a study published online July 26 in the Journal of Vision.

Abstract
Full Text

Clinicians Can Unintentionally Prompt Nocebo Effect

THURSDAY, Aug. 2 (HealthDay News) -- The nocebo effect, or induction of a symptom perceived as negative by sham treatment and/or the suggestion of negative expectation, may arise from suggestions by doctors and nurses, according to a study published in Deutsches Ärzteblatt International.

Full Text

Hypertension Ups Retinopathy Risk With HCV Treatment

THURSDAY, Aug. 2 (HealthDay News) -- For patients with hepatitis C virus (HCV) treated with pegylated interferon alpha (PegIFNα) and ribavirin, retinopathy occurs frequently, especially in those with hypertension, according to a study published in the August issue of Hepatology.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 ScoutNews, LLC. All rights reserved.


Previous: August 2012 Briefing - Hematology & Oncology Next: August 2012 Briefing - Orthopedics

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.